Literature DB >> 1477671

Detection of mutation delta F508 in the cystic fibrosis gene using allele-specific PCR primers and time-resolved fluorometry.

A Iitiä1, E Høgdall, P Dahlen, P Hurskainen, J Vuust, H Siitari.   

Abstract

A method to detect the main cystic fibrosis (CF) mutation delta F508 from dried blood spots, whole blood, or saliva using the polymerase chain reaction (PCR) and time-resolved fluorometry (TRF) is described. Samples are treated by boiling in mild alkaline solution, after which two allele-specific PCR reactions are performed. Allele-specific primers and a common biotinylated primer are used in the amplification reactions. To detect the PCR product, an europium-labeled oligonucleotide, complementary to the biotinylated strand of the PCR product, is used in a solution hybridization. Hybridization is done in streptavidin-coated microtitration wells, making the detection easy to perform. After a washing step, the bound label is detected using a time-resolved fluorometer. To analyze function of the assay, 20 dried blood spot samples were tested. PCR amplification of the deletion region combined with gel retardation assay was used as a control method. In the initial testing, 2 samples giving discrepant results in the two assays were found. In addition, 17 samples from known CF patients together with 6 normal control samples were analyzed. Among these patient samples, 10 homozygotes and 6 carriers for mutation delta F508 were found.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477671     DOI: 10.1101/gr.2.2.157

Source DB:  PubMed          Journal:  PCR Methods Appl        ISSN: 1054-9803


  2 in total

1.  Solid-phase synthesis of chelate-labelled oligonucleotides: application in triple-color ligase-mediated gene analysis.

Authors:  M Kwiatkowski; M Samiotaki; U Lamminmäki; V M Mukkala; U Landegren
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

Review 2.  Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications (Review).

Authors:  Tao Wei; Hongshu Sui; Yanping Su; Wanjing Cheng; Yunhua Liu; Zilin He; Qingchao Ji; Changlong Xu
Journal:  Mol Med Rep       Date:  2020-10-16       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.